NCT02499003View on ClinicalTrials.gov

GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 14, 2015

Primary Completion Date

January 2, 2019

Study Completion Date

January 2, 2022

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG

Obinutuzumab and Pixantrone

Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles, Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle

Trial Locations (1)

55131

Department of Hematology, Oncology and Pneumology; University Medical Center of the Johannes Gutenberg-University, Mainz

All Listed Sponsors

collaborator

Roche Pharma AG

INDUSTRY

collaborator

Servier

INDUSTRY

lead

Johannes Gutenberg University Mainz

OTHER

NCT02499003 - GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma | Biotech Hunter | Biotech Hunter